At the news
? BULLISHIMPACT 7/10 8-K filed May 27, 2026 at 06:40 ET
Apogee Therapeutics entered into a revenue participation agreement with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, including an upfront $100 million and up to $800 million in synthetic royalty funding for zumilokibart, plus access to $500 million in senior debt. The company also withdrew its cash runway guidance, signaling confidence in its financial position. Combined with its existing $1.3 billion cash, this positions Apogee to fund Phase 3 development and potential commercialization without equity dilution.
- Upfront payment of $100 million from Blackstone Life Sciences for revenue share on zumilokibart sales.
- Up to $800 million total synthetic royalty funding: $100M at signing, $100M upon Phase 3 enrollment, $200M upon positive Phase 3 data, and up to $400M upon FDA approval.
- Up to $500 million in senior corporate debt available at mutual consent.
- Apogee has $1.3 billion in current total cash, combined with the new capital to achieve self-sustainable profile without future equity financing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access